Distinguished in Primary Hyperoxaluria Type 2

Bernd Hoppe

Bonn, NW, DE 
Distinguished in Primary Hyperoxaluria Type 2
Bonn, NW, DE 
OverviewLocationsClinical Research

Overview

Bernd Hoppe practices in Bonn, Germany. Mr. Hoppe is rated as a Distinguished expert by MediFind in the treatment of Primary Hyperoxaluria Type 2. His top areas of expertise are Primary Hyperoxaluria, Nephrocalcinosis, Primary Hyperoxaluria Type 1, Kidney Transplant, and Liver Transplant.

His clinical research consists of co-authoring 129 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Primary Hyperoxaluria Type 2.

Gender
Male

Locations

Bonn, NW, Germany
Other Locations
Mainz, RP 55122, Germany
Koeln, NW, Germany
Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)
A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis
A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis
Enrollment Status: Completed
Publish Date: January 10, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
Enrollment Status: Completed
Publish Date: December 10, 2021
Intervention Type: Other, Biological
Study Drug: Oxabact OC5 - Oxalobacter formigenes HC-1
Study Phase: Phase 3
View 2 Less Clinical Trials

129 Total Publications

RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1 (PH1).
RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1 (PH1).
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: October 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hoppe's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile